Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Fair Value Disclosures [Abstract]
Net (gains)/losses recognized during the period on equity securities	[1],[2]	$ 699	$ (401)
Less: Net (gains)/losses recognized during the period on equity securities sold during the period		(11)	(28)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date	[3]	$ 710	$ (372)

[1] Reported in Other (income)/deductions––net. See Note 4.

[2] The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech.

[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 3, 2022, there were cumulative impairments and downward adjustments of $110 million and upward adjustments of $167 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021.